Stock 600867 TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tonghua Dongbao Pharmaceutical Co., Ltd.

Equities

600867

CNE000000H87

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
10.28 CNY -1.44% Intraday chart for Tonghua Dongbao Pharmaceutical Co., Ltd. +1.88% -5.08%
11:35am Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake MT
08/05 JHM Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Tonghua Dongbao Pharmaceutical Co., Ltd. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 25,730 26,999 22,161 18,210 21,483 20,269 - -
Enterprise Value (EV) 1 25,487 26,406 21,296 17,422 20,528 18,023 18,423 17,174
P/E ratio 31.6 x 29.1 x 17.1 x 11.6 x 18.4 x 16.7 x 14.3 x 13.2 x
Yield 1.58% 1.57% 2.74% 2.72% 2.31% 2.24% 2.63% 2.69%
Capitalization / Revenue 9.26 x 9.34 x 6.78 x 6.55 x 6.99 x 6.1 x 5.28 x 4.83 x
EV / Revenue 9.18 x 9.13 x 6.52 x 6.27 x 6.67 x 5.42 x 4.8 x 4.1 x
EV / EBITDA 22.7 x 19.8 x 12.6 x 8.88 x - 11.2 x 9.82 x 8.72 x
EV / FCF 2,96,68,309 x 3,69,84,384 x - - - - - -
FCF Yield 0% 0% - - - - - -
Price to Book 5.15 x 4.9 x 3.59 x 2.8 x 2.99 x 2.57 x 2.28 x 2.04 x
Nbr of stocks (in thousands) 20,33,989 20,17,889 20,21,989 19,83,679 19,83,617 19,71,734 - -
Reference price 2 12.65 13.38 10.96 9.180 10.83 10.28 10.28 10.28
Announcement Date 14/04/20 14/01/21 24/01/22 06/02/23 29/01/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,777 2,892 3,268 2,778 3,075 3,322 3,839 4,193
EBITDA 1 1,121 1,335 1,693 1,963 - 1,611 1,875 1,969
EBIT 1 967.8 1,181 1,549 1,829 1,365 1,386 1,684 1,798
Operating Margin 34.85% 40.82% 47.41% 65.82% 44.39% 41.72% 43.86% 42.88%
Earnings before Tax (EBT) 1 952.5 1,108 1,534 1,830 1,366 1,387 1,686 1,802
Net income 1 811.2 929.9 1,308 1,582 1,168 1,205 1,441 1,552
Net margin 29.21% 32.15% 40.03% 56.93% 37.97% 36.27% 37.54% 37.02%
EPS 2 0.4000 0.4600 0.6400 0.7900 0.5900 0.6150 0.7212 0.7780
Free Cash Flow 859.1 714 - - - - - -
FCF margin 30.93% 24.69% - - - - - -
FCF Conversion (EBITDA) 76.65% 53.47% - - - - - -
FCF Conversion (Net income) 105.9% 76.78% - - - - - -
Dividend per Share 2 0.2000 0.2100 0.3000 0.2500 0.2500 0.2300 0.2702 0.2767
Announcement Date 14/04/20 14/01/21 24/01/22 06/02/23 29/01/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 812.9 887.5 500 711.5 679.4 665.4 701 725.2 983.9 591.4 708.5 841.8 1,029 812.9 879
EBITDA - - - - - - - - - - - - - - -
EBIT 1 289.5 980.4 403.4 259.4 185.7 289.6 272.9 316.5 486.1 238.9 306.3 338.8 389.1 343.1 -
Operating Margin 35.61% 110.47% 80.67% 36.46% 27.33% 43.53% 38.93% 43.65% 49.4% 40.39% 43.23% 40.25% 37.82% 42.21% -
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income - - - - - - - - - 214.7 - - - - -
Net margin - - - - - - - - - 36.3% - - - - -
EPS 2 0.1200 0.4100 0.1800 0.1100 0.0900 0.1300 0.1100 0.1400 0.2100 0.1100 0.1300 0.1500 0.1750 0.1550 0.1500
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 24/01/22 28/04/22 30/08/22 30/10/22 06/02/23 26/04/23 21/08/23 30/10/23 29/01/24 27/04/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 243 593 865 788 954 2,246 1,846 3,096
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 859 714 - - - - - -
ROE (net income / shareholders' equity) 16.6% 17.7% 22.1% 24.5% 17.1% 16.1% 17.1% 16.6%
ROA (Net income/ Total Assets) 15% 16.8% 21.6% 23.8% - 16% 16.2% 15.4%
Assets 1 5,407 5,532 6,062 6,635 - 7,532 8,911 10,054
Book Value Per Share 2 2.460 2.730 3.060 3.280 3.620 4.000 4.510 5.040
Cash Flow per Share 2 0.5700 0.5900 0.5600 0.4300 0.4300 0.6600 0.7600 0.7700
Capex 1 293 478 580 492 348 314 311 455
Capex / Sales 10.55% 16.54% 17.76% 17.69% 11.31% 9.46% 8.1% 10.85%
Announcement Date 14/04/20 14/01/21 24/01/22 06/02/23 29/01/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Tonghua Dongbao Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.28 CNY
Average target price
14.36 CNY
Spread / Average Target
+39.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. Stock Tonghua Dongbao Pharmaceutical Co., Ltd.
-5.08% 2.85B
CSL LIMITED Stock CSL Limited
-2.61% 88.47B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.55% 40.71B
BIOGEN INC. Stock Biogen Inc.
-14.01% 32.43B
UCB Stock UCB
+55.89% 24.28B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.84% 15.52B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-41.29% 12.17B
INCYTE CORPORATION Stock Incyte Corporation
-15.50% 12.01B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.75% 12B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.87% 8.87B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 600867 Stock
  4. Financials Tonghua Dongbao Pharmaceutical Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW